Six Robert H, Everett William R, Young David R, Carter Lori, Mahabir Sean P, Honsberger Nicole A, Myers Melanie R, Holzmer Susan, Chapin Sara, Rugg Jady J
Zoetis, Veterinary Medicine Research and Development, 333 Portage St., Kalamazoo, MI 49007 USA.
BerTek, Inc. PO Box 606, Greenbrier, AR 72058 USA.
Vet Parasitol. 2016 May 30;222:28-32. doi: 10.1016/j.vetpar.2015.12.023. Epub 2015 Dec 28.
The efficacy of a single oral treatment with sarolaner (Simparica™, Zoetis), a novel isoxazoline compound, was evaluated against five tick species known to infest dogs in the United States. A total of 10 laboratory studies, two against each species, were conducted using adult purpose-bred mongrels or Beagle dogs. In each study, 16 dogs were randomly allocated to one of two treatment groups based on pre-treatment host-suitability tick counts. Dogs were infested with approximately 50 unfed adult Amblyomma americanum, Amblyomma maculatum, Dermacentor variabilis, Ixodes scapularis or Rhipicephalus sanguineus ticks on Days -2, 5, 12, 19, 26 and 33. On Day 0, dogs were treated with a placebo or a sarolaner tablet providing a minimum dose of 2 mg/kg. Tick counts were conducted 48h after treatment and after each subsequent weekly re-infestation. There were no treatment-related adverse reactions during any of the studies. Dogs in the placebo-treated group maintained tick infestations throughout the studies. Geometric mean live tick counts were significantly lower (P≤0.0001) in the sarolaner-treated group compared to the tick counts in the placebo group at all timepoints. Treatment with sarolaner resulted in ≥99.6% efficacy against existing infestations of all five tick species within 48h. The efficacy against weekly post-treatment re-infestations of all tick species was ≥96.9% for at least 35 days after treatment. Thus, a single dose of sarolaner administered orally at the minimum dosage of 2mg/kg, resulted in excellent efficacy within 48h against existing tick infestations, and against weekly re-infestations for 35 days after treatment. These studies confirmed that administration of the minimum dose of sarolaner will provide rapid treatment of existing infestations and give at least one month of control against re-infestation by the common tick species affecting dogs in the US.
对一种新型异恶唑啉化合物——沙罗拉纳（Simparica™，硕腾公司生产）进行单次口服治疗，评估其对美国已知寄生于犬类的五种蜱虫的疗效。使用成年的定向培育杂种犬或比格犬总共进行了10项实验室研究，每种蜱虫进行两项研究。在每项研究中，根据治疗前宿主适宜性蜱虫计数，将16只犬随机分配到两个治疗组之一。在第-2、5、12、19、26和33天，给犬感染约50只未进食的成年美洲钝眼蜱、斑点钝眼蜱、变异革蜱、肩突硬蜱或血红扇头蜱。在第0天，给犬服用安慰剂或一片沙罗拉纳片剂，提供的最小剂量为2mg/kg。在治疗后48小时以及随后每次每周再次感染后进行蜱虫计数。在任何一项研究中均未出现与治疗相关的不良反应。在整个研究过程中，安慰剂治疗组的犬一直有蜱虫寄生。在所有时间点，沙罗拉纳治疗组的几何平均存活蜱虫计数与安慰剂组相比均显著更低（P≤0.0001）。沙罗拉纳治疗在48小时内对所有五种蜱虫的现有感染的疗效≥99.6%。对所有蜱虫种类治疗后每周再次感染的疗效在治疗后至少35天内≥96.9%。因此，以2mg/kg的最小剂量口服一剂沙罗拉纳，在48小时内对现有蜱虫感染具有极佳疗效，并且在治疗后35天内对每周再次感染也有疗效。这些研究证实，给予最小剂量的沙罗拉纳将能快速治疗现有感染，并对影响美国犬类健康的常见蜱虫种类的再次感染提供至少一个月的防控效果。
